Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VAD 044

Next Previous
Drug Profile

VAD 044

Alternative Names: ALM-301; VAD-044

Latest Information Update: 30 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Almac Discovery
  • Developer Vaderis Therapeutics
  • Class Antineoplastics; Small molecules; Vascular disorder therapies
  • Mechanism of Action Proto-oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hereditary haemorrhagic telangiectasia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hereditary haemorrhagic telangiectasia; Vascular disorders
  • Preclinical Breast cancer; Prostate cancer

Most Recent Events

  • 30 Apr 2025 VAD 044 received Orphan Drug status for Hereditary haemorrhagic telangiectasia in European Union prior to April 2025 (Vaderis Therapeutics Pipeline, April 2025)
  • 30 Apr 2025 VAD 044 received Orphan Drug status for Hereditary haemorrhagic telangiectasia in USA prior to April 2025 (Vaderis Therapeutics Pipeline, April 2025)
  • 30 Apr 2025 Vaderis Therapeutics filed for Orphan drug designation for Vascular disorders prior to April 2025 (Vaderis Therapeutics Pipeline, April 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top